You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Functionalized, Therapeutic-Loaded Liposomes for the Acute Treatment of TBI

    SBC: LUNA INNOVATIONS INCORPORATED            Topic: DHA18A001

    Traumatic brain injury is a common problem in both the military and civilian communities, but current treatment protocols are focused on managing symptoms and fail to prevent significant long-term repercussions. In the proposed program, Luna will demonstrate the feasibility of a liposome-based therapeutic delivery system capable of delivering hydrophilic and hydrophobic therapeutics to the traumat ...

    STTR Phase I 2018 Department of DefenseDefense Health Agency
  2. Infectious Disease Diagnostics and Differentiation of Viral vs. Bacterial Infections for Point ofCare Applications

    SBC: GENECAPTURE, INC.            Topic: CBD15C001

    GeneCapture, Inc. is proposing to develop a rapid in vitro diagnostic prototype using our patented molecular-based CAPTURE (ConfirmActive Pathogens Through Unamplified RNA Expression) assay. Based on the results and experience gained in our Phase I STTR contractHDTRA1-16C-0061: Infectious Disease Diagnostics and Differentiation of Viral vs. Bacterial Infections for Point of Care Applications, we p ...

    STTR Phase II 2018 Department of DefenseOffice for Chemical and Biological Defense
  3. Medical Device to Assess the Viability of Tissue Prior to Skin Grafting

    SBC: Spectral Md, Inc.            Topic: DHP17A006

    The primary objective of this Phase II proposal is to construct and validate the portable SpectralMD DeepView imaging technology designed previously in Phase I. This device allows surgeons to quickly and objectively assess tissue viability in burn surgery prior to skin grafting. DeepView uses machine learning and multispectral imaging to generate quantitative prognostic images with easily interpre ...

    STTR Phase II 2018 Department of DefenseDefense Health Agency
  4. Novel Circulating RNA-based Markers as Diagnostic Biomarkers of Infectious Diseases

    SBC: CFD RESEARCH CORPORATION            Topic: CBD18A001

    In resource limited settings, rapid and accurate diagnosis of infections is critical for managing potential exposures to highly virulent pathogens,whether occurring from an act of bioterrorism or a natural event. This is especially important for hard to detect intracellular bacterial andalphavirus infections, that overlap symptomatically and often treated empirically due to a lack of reliable and ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  5. Probabilistic Pharmacokinetic Models for Diagnosis, Prognosis, and Personalized Treatment

    SBC: BARRON ASSOCIATES, INC.            Topic: DHA17B003

    Clinicians have recognized that the nature of diseases can be highly individual resulting in different patterns of onset and progression. In turn, the response of an individual to drugs is also unique and governed by a variety of factors. Pharmacokinetic models represent the movement of a drug through the body, and personalized pharmacokinetic models aim to capture the unique responses of specific ...

    STTR Phase I 2018 Department of DefenseDefense Health Agency
  6. Virus-Like Particle Based pan-Marburgvirus Vaccine

    SBC: LUNA INNOVATIONS INCORPORATED            Topic: CBD18A002

    Marburg virus (MARV) is a filamentous enveloped non-segmented negative sense RNA virus. This viruse is considered to be extremelydangerous with case fatality rates as high as 88-90%. Extensive efforts have gone towards effective vaccines for MARV prevention, however,none have been successfully established as licensed vaccines. Glycoprotein (GP) is the only surface protein of MARV. There are substa ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
US Flag An Official Website of the United States Government